BeOne Medicines AG
ONC
$335.17
$2.460.74%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 51.21% | 51.26% | 55.64% | 60.09% | 54.29% |
| Total Other Revenue | 111.86% | -- | -- | -- | -- |
| Total Revenue | 51.36% | 51.53% | 55.94% | 60.43% | 54.67% |
| Cost of Revenue | 28.18% | 46.88% | 55.39% | 62.62% | 163.43% |
| Gross Profit | 55.91% | 52.35% | 56.04% | 60.02% | -7.64% |
| SG&A Expenses | 18.88% | 21.86% | 19.65% | 25.49% | 23.12% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -105.26% | -350.57% | -350.57% | -350.57% | 202.14% |
| Total Operating Expenses | 15.51% | 20.53% | 19.38% | 23.22% | 22.53% |
| Operating Income | 121.50% | 88.86% | 72.93% | 52.47% | 31.70% |
| Income Before Tax | 126.29% | 90.44% | 65.25% | 36.63% | 16.55% |
| Income Tax Expenses | 103.56% | 135.20% | 157.07% | 117.68% | 8.54% |
| Earnings from Continuing Operations | 109.75% | 67.35% | 50.47% | 26.85% | 15.14% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 109.75% | 67.35% | 50.47% | 26.85% | 15.14% |
| EBIT | 121.50% | 88.86% | 72.93% | 52.47% | 31.70% |
| EBITDA | 144.70% | 109.97% | 87.43% | 63.33% | 38.97% |
| EPS Basic | 108.84% | 67.66% | 51.18% | 27.55% | 15.58% |
| Normalized Basic EPS | 118.56% | 95.20% | 77.44% | 56.35% | -24.43% |
| EPS Diluted | 106.44% | 65.86% | 50.98% | 26.28% | 15.01% |
| Normalized Diluted EPS | 117.65% | 94.64% | 77.36% | 56.35% | -24.43% |
| Average Basic Shares Outstanding | 3.05% | 2.19% | 1.34% | 0.73% | 0.28% |
| Average Diluted Shares Outstanding | 6.10% | 4.22% | 2.35% | 0.73% | 0.28% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -1.85% | -0.88% | -0.27% | -0.10% |